Pharma Mar, S.A.

Total Valuation

Pharma Mar, S.A. carries a market capitalization of 1.84B, placing it among publicly traded companies globally. Its enterprise value stands at 1.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Pharma Mar, S.A. currently has 17.43M shares outstanding.

Valuation Ratios

Pharma Mar, S.A. trades at a trailing price-to-earnings ratio of 29.83. The price-to-sales ratio is 5.83, and the price-to-book ratio stands at 6.87.

Enterprise Valuation

On an enterprise value basis, Pharma Mar, S.A. trades at an EV/EBITDA multiple of 35.33 and an EV/FCF ratio of 66.50. The EV/Sales ratio of 5.50 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 35.33 provides insight into valuation relative to core operating earnings.

Financial Position

Pharma Mar, S.A. maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.50, indicating elevated leverage, while an interest coverage ratio of 12.63 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Pharma Mar, S.A.'s stock has gained approximately 2.77799% over the past 52 weeks. The 50-day moving average sits at 87.88, while the 200-day moving average is 92.53.

Income Statement

Over the trailing twelve months, Pharma Mar, S.A. generated 234.92M in revenue and converted that into 45.91M in net income, yielding earnings per share of 2.63. EBITDA reached 36.60M, while operating income came in at 36.60M.

Balance Sheet

Pharma Mar, S.A. holds 128.08M in cash and equivalents against 51.40M in total debt, resulting in a net debt position of 26.74M. Total book value stands at 199.36M, with working capital of 161.62M providing operational flexibility.

Cash Flow

Pharma Mar, S.A. produced 8.80M in operating cash flow over the past twelve months. After subtracting -7.02M in capital expenditures, free cash flow totaled 1.78M - equivalent to 0.10 per share.

Margins

Pharma Mar, S.A. operates with a gross margin of 94.22, reflecting its pricing power and cost economics. The operating margin of 15.58 and net profit margin of 19.54 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Pharma Mar, S.A.'s most recent stock split took place on July 22, 2020 with a 12:1 split ratio.

Scores

Pharma Mar, S.A. posts an Altman Z-Score of 7.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.